Vivimed Labs share news and announcements
NSE: VIVIMEDLABBSE: 532660Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹6.21.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹50 Cr3,293rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, NSEVolume. Shares traded on the last trading day.
- 75
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Vivimed Labs quarterly results
The board met on 17 Jul 2026 to consider financial results
Notice filed 14 Jul 2026
Vivimed Labs annual reports, presentations and earnings calls
The company's own documents, latest first.Vivimed Labs financials, year by year
Annual reports14
- Annual report, year to Mar 2025 (opens in a new tab)6 Sep 2025
- Annual report, year to Mar 2024 (opens in a new tab)11 Dec 2024
- Annual report, year to Mar 2023 (opens in a new tab)20 Oct 2023, a zip file
- Annual report, year to Mar 2021 (opens in a new tab)13 Jan 2023, a zip file
- Annual report, year to Mar 2022 (opens in a new tab)13 Jan 2023, a zip file
9 earlier reports
- Annual report, year to Mar 2020 (opens in a new tab)24 Dec 2020, a zip file
- Annual report, year to Mar 2018 (opens in a new tab)19 Oct 2018, a zip file
- Annual report, year to Mar 2017 (opens in a new tab)16 Oct 2017, a zip file
- Annual report, year to Mar 2016 (opens in a new tab)13 Oct 2016, a zip file
- Annual report, year to Mar 2015 (opens in a new tab)14 Sep 2015, a zip file
- Annual report, year to Mar 2014 (opens in a new tab)10 Sep 2014, a zip file
- Annual report, year to Mar 2013 (opens in a new tab)21 Nov 2013, a zip file
- Annual report, year to Mar 2012 (opens in a new tab)21 Oct 2013, a zip file
- Annual report, year to Mar 2011 (opens in a new tab)25 Oct 2011, a zip file
Investor presentations10
- Investor Presentation (opens in a new tab)20 Aug 2019
- Investor Presentation (opens in a new tab)7 Mar 2019
- Investor Presentation (opens in a new tab)27 Nov 2018
- Investor Presentation (opens in a new tab)14 Aug 2018, a zip file
- Investor Presentation (opens in a new tab)2 Jun 2018, a zip file
5 earlier presentations
- Investor Presentation (opens in a new tab)15 Feb 2018, a zip file
- Investor Presentation (opens in a new tab)15 Nov 2017, a zip file
- Investor Presentation (opens in a new tab)14 Aug 2017, a zip file
- Earnings Presentation on Q2 FY2017 results. (opens in a new tab)16 Nov 2016, a zip file
- Earnings Presentation for Q1. (opens in a new tab)16 Aug 2016, a zip file
Vivimed Labs share news and announcements
653 announcements, routine notices left out, newest first. Page 1 of 14.
Oct 2026
22 Oct · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Impact of Audit Qualifications in case of modified opinion(s) The response of the Company is awaited.15 Oct · Board meeting
Sep 2026
28 Sep · Updates
Aug 2026
Jul 2026
31 Jul · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.22 Jul · Updates
17 Jul · Results
Jun 2026
May 2026
30 May · Updates
26 May · Board meeting
Not held on this date
19 May · Updates
Apr 2026
6 Apr · Updates
Mar 2026
Feb 2026
16 Feb · Updates
9 Feb · Disclosure of material issue
6 Feb · Disclosure of material issue
3 Feb · Disclosure of material issue
2 Feb · Board meeting
Not held on this date
Jan 2026
13 Jan · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.6 Jan · Legal
The exchange asked on 5 Jan 2026
Dec 2025
Nov 2025
21 Nov · General Updates
21 Nov · General Updates
13 Nov · Updates
Oct 2025
Sep 2025
8 Sep · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts).
- 16 Mar 2026Resultsdown 3.92%−4.4 pts vs Nifty 500market median −0.7% · five sessions −8.7% (−8.4 pts vs Nifty 500) · volume 0.6× usual · delivery −7.1 pts against usual · The announcement (opens in a new tab)
- 16 Aug 2022Resultsdown 0.99%−1.9 pts vs Nifty 500market median −0.7% · five sessions −1.5% (−0.6 pts vs Nifty 500) · volume 1.1× usual · delivery +1.7 pts against usual · The announcement (opens in a new tab)
- 10 Jan 2022Board or managers changedup 6.33%+5.4 pts vs Nifty 500market median 0.0% · five sessions +5.0% (+2.5 pts vs Nifty 500) · volume 2.4× usual · delivery −0.9 pts against usual · The announcement (opens in a new tab)
- 18 Oct 2021Board or managers changeddown 1.62%−2.4 pts vs Nifty 500market median 0.0% · five sessions −7.4% (−5.1 pts vs Nifty 500) · volume 0.9× usual · delivery +6.2 pts against usual · The announcement (opens in a new tab)
- 6 Jan 2020Board or managers changeddown 5.75%−3.8 pts vs Nifty 500market median 0.0% · five sessions −5.0% (−5.3 pts vs Nifty 500) · volume 0.7× usual · delivery +7.6 pts against usual · The announcement (opens in a new tab)
- 15 Nov 2019Resultsdown 6.79%−7.0 pts vs Nifty 500market median −0.7% · five sessions −7.1% (−7.8 pts vs Nifty 500) · volume 8.3× usual · delivery +7.7 pts against usual · The announcement (opens in a new tab)
- 31 May 2018Dividendup 1.54%+0.9 pts vs Nifty 500market median 0.0% · five sessions −1.0% (−0.4 pts vs Nifty 500) · volume 2.8× usual · delivery −14.4 pts against usual · The announcement (opens in a new tab)
- 29 May 2017Dividendup 1.99%+2.4 pts vs Nifty 500market median 0.0% · five sessions −1.7% (−2.6 pts vs Nifty 500) · volume 3.5× usual · delivery −6.2 pts against usual · The announcement (opens in a new tab)
- 18 Dec 2015Board or managers changeddown 0.75%0.0 pts vs Nifty 500market median 0.0% · five sessions +3.6% (+3.1 pts vs Nifty 500) · volume 0.4× usual · The announcement (opens in a new tab)
- 19 Mar 2015Board or managers changeddown 1.69%−1.1 pts vs Nifty 500market median 0.0% · five sessions −6.3% (−4.0 pts vs Nifty 500) · volume 0.2× usual · The announcement (opens in a new tab)
10 earlier announcements
- 30 May 2014Dividenddown 3.52%−3.6 pts vs Nifty 500market median 0.0% · five sessions −1.7% (−5.8 pts vs Nifty 500) · volume 0.5× usual
- 3 Jun 2013Dividenddown 0.59%−0.1 pts vs Nifty 500market median 0.0% · five sessions +0.4% (+1.7 pts vs Nifty 500) · volume 0.3× usual
- 31 May 2012Dividenddown 0.88%−0.6 pts vs Nifty 500market median 0.0% · five sessions +0.3% (−0.6 pts vs Nifty 500) · volume 0.6× usual
- 30 May 2011Dividenddown 1.94%−2.2 pts vs Nifty 500market median 0.0% · five sessions −3.4% (−4.5 pts vs Nifty 500) · volume 1.7× usual
- 17 Aug 2010Dividenddown 4.57%−4.7 pts vs Nifty 500market median 0.0% · five sessions +4.2% (+2.0 pts vs Nifty 500) · volume 1.0× usual
- 2 Sep 2009Buybackup 5.01%+5.4 pts vs Nifty 500market median 0.0% · five sessions +8.1% (+4.7 pts vs Nifty 500) · volume 3.6× usual
- 3 Jul 2009Dividenddown 1.02%−2.2 pts vs Nifty 500market median 0.0% · five sessions −8.6% (−2.3 pts vs Nifty 500) · volume 0.2× usual
- 24 Dec 2008Board or managers changedup 7.41%+8.8 pts vs Nifty 500market median 0.0% · five sessions +4.4% (+4.0 pts vs Nifty 500) · volume 5.7× usual
- 8 Sep 2008Dividenddown 0.34%−2.8 pts vs Nifty 500market median 0.0% · five sessions −1.1% (+2.1 pts vs Nifty 500) · volume 0.5× usual
- 30 Jun 2008Dividenddown 5.98%−3.2 pts vs Nifty 500market median 0.0% · five sessions −10.5% (−7.0 pts vs Nifty 500) · volume 0.5× usual
Vivimed Labs results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.
Figures filed again
The latest 30. Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | At Mar 2025 | Consolidated | 0.71 | 0.21 | −70.6% | 31 May 2025 (opens in a new tab) | 21 Jul 2025 (opens in a new tab) |
| Reserves | Year to Mar 2025 | Consolidated | 3.91 | −51.75 | −1,424.3% | 31 May 2025 (opens in a new tab) | 21 Jul 2025 (opens in a new tab) |
| Reserves | Year to date to Mar 2025 | Consolidated | 3.91 | −51.75 | −1,424.3% | 31 May 2025 (opens in a new tab) | 21 Jul 2025 (opens in a new tab) |
| Total expenses | Quarter to Mar 2025 | Consolidated | 34.84 | 34.86 | 0.0% | 31 May 2025 (opens in a new tab) | 21 Jul 2025 (opens in a new tab) |
| Profit before tax | Quarter to Mar 2025 | Consolidated | −5.01 | −5.02 | −0.2% | 31 May 2025 (opens in a new tab) | 21 Jul 2025 (opens in a new tab) |
| Total assets | At Mar 2025 | Standalone | 638.95 | 638.95 | 0.0% | 31 May 2025 (opens in a new tab) | 21 Jul 2025 (opens in a new tab) |
| Dealing with a related party in the period | Quarter to Mar 2025 | Standalone | 17.03 | 21.18 | +24.4% | 31 May 2025 (opens in a new tab) | 21 Jul 2025 (opens in a new tab) |
| Cash and cash equivalents | At Mar 2025 | Standalone | 0.29 | 0.20 | −31.1% | 31 May 2025 (opens in a new tab) | 21 Jul 2025 (opens in a new tab) |
| Total equity and liabilities | At Mar 2025 | Standalone | 638.95 | 638.95 | 0.0% | 31 May 2025 (opens in a new tab) | 21 Jul 2025 (opens in a new tab) |
| Net worth | At Mar 2025 | Standalone | 58.49 | 58.49 | 0.0% | 31 May 2025 (opens in a new tab) | 21 Jul 2025 (opens in a new tab) |